Patrick A May

US Patent:

56864760, Nov 11, 1997

Filed:

Mar 15, 1995

Appl. No.:

8/404700

Inventors:

Patrick C. May - Carmel IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31445

US Classification:

514324

Abstract:

This invention encompasses methods for the inhibition of Alzheimer's Disease comprising administering to a human in need thereof an effective amount of a compound of Formula I ##STR1## wherein R. sup. 1 and R. sup. 3 are independently hydrogen, --CH. sub. 3, ##STR2## wherein Ar is optionally substituted phenyl; R. sup. 2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof. The present invention also provides methods of increasing TGF-. beta. expression in the brain, comprising administering to a human in need thereof an effective amount of a compound of formula 1. The present invention also provides methods of inhibiting the. beta. -amyloid peptide mediated neurotoxicity or inflammatory response associated with Alzheimer's Disease (AD) comprising administering to a human in need thereof an effective amount of a compound of formula 1.

US Patent:

56522592, Jul 29, 1997

Filed:

May 9, 1996

Appl. No.:

8/645013

Inventors:

Patrick C. May - Carmel IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3140

US Classification:

514422

Abstract:

This invention encompasses methods for the inhibition of Alzheimer's Disease comprising administering to a human in need thereof an effective amount of a compound of Formula I ##STR1## wherein R. sup. 1 and R. sup. 3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R. sup. 2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof. The present invention also provides methods of increasing TGF-. beta. expression in the brain, comprising administering to a human in need thereof an effective amount of a compound of formula 1. The present invention also provides methods of inhibiting the. beta. -amyloid peptide mediated neurotoxicity or inflammatory response associated with Alzheimer's Disease (AD) comprising administering to a human in need thereof an effective amount of a compound of formula 1.

US Patent:

55524150, Sep 3, 1996

Filed:

Dec 21, 1993

Appl. No.:

8/171387

Inventors:

Patrick C. May - Carmel IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 31445
A61K 3138

US Classification:

514324

Abstract:

This invention encompasses methods for the inhibition of Alzheimer's Disease comprising administering to a human in need thereof an effective amount of a compound of Formula I ##STR1## wherein R. sup. 1 and R. sup. 3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R. sup. 2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof. The present invention also provides methods of increasing TGF-. beta. expression in the brain, comprising administering to a human in need thereof an effective amount of a compound of formula 1. The present invention also provides methods of inhibiting the. beta. -amyloid peptide mediated neurotoxicity or inflammatory response associated with Alzheimer's Disease (AD) comprising administering to a human in need thereof an effective amount of a compound of formula 1.